MYD88 and MALT lymphoma: Prior studies have shown evidence that immune mediators such as the CD40/40L signaling pathway, B‐cell receptor engagement, and NF‐kB activation may play roles in the development of MALT lymphoma, with mutations in genes involved in the NF‐kB pathway such as A20, Card11, CD79B, and Myd88 being most frequently involved [7, 8, 9].